Initially, the study included patients with MET amplification/overexpression (IHC 3+ expression in ≥50% of tumor cells or FISH GCN ≥ 5) in patients on progression on any line of osimertinib (≤3), determined by means of liquid or tissue biopsy and centrally confirmed. Here, MET is linked to neoplasm.